India is likely to consider rolling reviews for Covid-19 vaccine, particularly the Oxford-AstraZeneca developed candidate, to further fast-track the approval of the shots in the current pandemic situation. Oxford-AstraZeneca is already under the accelerated review of the UK health regulator. A rolling review will enable the regulator to examine the data generated through clinical trials on a real-time basis instead of waiting for the trial to be over and full data to be available for evaluation at once. ‘We are watching global developments closely. The serum is doing only immunogenicity trials in India. They will have to submit the Phase 3 clinical trial data generated in the UK and Brazil to us for review. We are aware that the UK is now conducting the accelerated review. We too can consider the same if the company makes an application for the same,’ a senior official working with the National Expert Group on Vaccine Administration for Covid-19 said.